JAMA. 2025 Jan 17. IF: 63.1Experts Are Debating Whether Some Cancers Shouldn't Be Called That.www.jamanetwork.com/journals/jama/fullarticle/2829485 Nat Med. 2025 Jan 17. IF: 58.7Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.www.nature.com/articles/s41591-024-03462-0 Nature. 2025 Jan 17. IF: 50.5How to trick the immune system into attacking tumours.www.nature.com/articles/d41586-025-00126-y J Clin Oncol. 2025 Jan 17. IF: 42.1Clonal Hematopoiesis in Women With Breast Cancer.www.ascopubs.org/doi/10.1200/JCO-24-01848 Nat Cancer. 2025 Jan 17. IF: 23.5Selective deficiency of mitochondrial respiratory complex I subunits Ndufs4/6 causes tumor immunogenicity.www.nature.com/articles/s43018-024-00895-x Cancer Commun (Lond). 2025 Jan 18. IF: 20.1Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.www.onlinelibrary.wiley.com/doi/10.1002/cac2.12662 ACS Nano. 2025 Jan 17. IF: 15.8Targeted Modulation of the Meningeal Lymphatic Reverse Pathway for Immunotherapy of Breast Cancer Brain Metastases.pubs.acs.org/doi/10.1021/acsnano.4c15860 Nat Commun. 2025 Jan 17;16(1):762. IF: 14.7Aggregation control of anionic pentamethine cyanine enabling excitation wavelength selective NIR-II fluorescence imaging-guided photodynamic therapy.www.nature.com/articles/s41467-024-55429-x Nat Protoc. 2025 Jan 17. IF: 13.1Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture.www.nature.com/articles/s41596-024-01077-w Drugs. 2025 Jan 17. IF: 13.0Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2- Early Breast Cancer.link.springer.com/article/10.1007/s40265-024-02144-y Biomaterials. 2025 Jan 15;317:123105. IF: 12.8Molecularly manipulating pyrazinoquinoxaline derivatives to construct NIR-II AIEgens for multimodal phototheranostics of breast cancer bone metastases.www.sciencedirect.com/science/article/pii/S0142961225000249 J Immunother Cancer. 2025 Jan 16;13(1):e010013. IF: 10.3Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.jitc.bmj.com/content/13/1/e010013 Genome Biol. 2025 Jan 17;26(1):10. IF: 10.1Enhancer regulatory networks globally connect non-coding breast cancer loci to cancer genes.www.biomedcentral.com/articles/10.1186/s13059-025-03474-0 Clin Cancer Res. 2025 Jan 16. IF: 10.0Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial.www.aacrjournals.org/clincancerres/article/751132 Adv Healthc Mater. 2025 Jan 16. IF: 10.0Engineered Age-Mimetic Breast Cancer Models Reveal Differential Drug Responses in Young and Aged Microenvironments.www.onlinelibrary.wiley.com/doi/10.1002/adhm.202404461 EMBO Mol Med. 2025 Jan 16. IF: 9.0Gut microbiota interact with breast cancer therapeutics to modulate efficacy.www.embopress.org/doi/10.1038/s44321-024-00185-0 NPJ Precis Oncol. 2025 Jan 17;9(1):18. IF: 6.8Prediction of post-treatment recurrence in early-stage breast cancer using deep-learning with mid-infrared chemical histopathological imaging.www.nature.com/articles/s41698-024-00772-x
